Quote | Immuneering Corporation (NASDAQ:IMRX)
Last: | $1.56 |
---|---|
Change Percent: | 0.0% |
Open: | $1.63 |
Close: | $1.56 |
High: | $1.63 |
Low: | $1.52 |
Volume: | 176,052 |
Last Trade Date Time: | 05/09/2024 03:00:00 am |
News | Immuneering Corporation (NASDAQ:IMRX)
2024-05-08 10:50:01 ET More on Immuneering Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone Seeking Alpha's Quant Rating on Immuneering Historical earnings data for Immuneering Read the full article on Seeking Alpha For f...
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - ...
Message Board Posts | Immuneering Corporation (NASDAQ:IMRX)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Immuneering Corporation Company Name:
IMRX Stock Symbol:
NASDAQ Market:
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - ...
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...